CROSSJECT is an emerging specialty pharmaceutical company developing medications dedicated to emergency situations, leveraging its proprietary platform built around the award-winning ZENEO® needle-free auto-injector. The company is in advanced regulatory development for ZEPIZURE®, an emergency treatment for managing epileptic seizures, for which CROSSJECT has secured a $60 million contract* with the U.S. Biomedical Advanced Research and Development Authority (BARDA).
The versatile ZENEO® platform is designed to enable untrained patients or caregivers to easily and instantly administer a wide range of emergency medications via intramuscular injection, either on bare skin or through clothing. The company is also developing additional products focused on treating allergic shocks, adrenal insufficiency, and other emergency medicine indications, as well as therapies for other critical conditions.
* BARDA Contract Number: 75A50122C00031. This contract was signed with BARDA, which operates under the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS).
Three targeted products (epileptic seizures, acute adrenal insufficiency crisis, allergic shock) addressing unmet medical needs where patients’ lives are at stake.
Strengthening presence for commercialization in the USA, starting with ZEPIZURE®.
In 2022, BARDA placed a firm order worth $60 million with CROSSJECT for an initial delivery to the U.S. Strategic National Stockpile, contingent upon FDA authorization. BARDA also funds the continued development and regulatory activities for ZEPIZURE® in the United States until FDA approval is obtained. Additionally, BARDA holds an option to purchase additional auto-injectors from CROSSJECT. The total value of the contract, if all options are exercised, would amount to $155 million.
* BARDA Contract Number: 75A50122C00031. This contract was signed with BARDA, which operates under the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS).
Copyright © 2024 CROSSJECT – VERSION BETA TEST